Prof. Michael Bergmann, M.D.
Scientific Co-Founder, CMO
Dr. Michael Bergmann received his MD from the Medical University of Vienna (MUV). From 1990-1994 he was a postdoctoral fellow with Dr. Peter Palese at the Icahn School of Medicine at Mount Sinai, New York where he developed the first prototypes of influenza vaccine viruses based on an emerging rational understanding of the viral biology. He did so by using the then novel technology of viral engineering. Thereafter he started a carrier as a physician scientist and a surgeon at the MUV. There he established his own translational group at the surgical research lab. He was appointed professor of the department in 2003 and head of the surgical research labs in 2010. Combining his knowledge of genetic viral engineering and tumor immunology he developed the first oncolytic influenza virus and continued to work on the virus host interactions as this is the prerequisite for an effective development of oncolytic viruses. Dr. Bergmann also contributed to 3 EU projects, which were designed to develop influenza virus based vaccines up to clinical phase I. He published more than 50 scientific papers in the fields of virology and molecular oncology